At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 77 enrolled
Drug / intervention
Caelyxdrug
Likely dose
Caelyx (PLD) 40 mg/m² biweeklyAI-extracted
Key inclusion· 6
- ✓Age ≥18 years
- ✓Recurrent ovarian, peritoneal, or tubal cancer with prior platinum and paclitaxel treatment
- ✓ECOG performance status <3
- ✓Adequate renal function: serum creatinine ≤1.25× ULN and GFR >60 mL/min
Key exclusion· 2
- ✕More than 4 prior chemotherapy regimens
- ✕Severe cardiac disease
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of Quality of Life in Patients With Platinum-sensitive Recurrent Ovarian, Fallopian Tube and Peritoneal Cancer When Treated With Treatment With Trabectedin/PLD or Standard Platinum-based Therapy
North Eastern German Society of Gynaecological Oncology·interventional·Posted Sep 15, 2005·Updated Dec 16, 2024
In Brief
A Phase 2 clinical trial evaluating Caelyx for Ovarian Cancer. Completed, enrolled 77 participants.
Detailed Summary
Effect of biweekly schedule of PLD on dose-limiting toxicity of PPE and patient's quality of life
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2001
First PostedSep 2005
Primary CompletionApr 2009
Study CompletionAug 2010
TodayJul 2026
First PostedSep 15, 2005
Enrollment StartSep 1, 2001
Primary CompletionApr 1, 2009
Study CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 7.6 yearsPosted 20.8 years ago
Interventions
Caelyxdrug
40 mg/m² biweekly